Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 reverse transcriptase (RT) is a multifunctional enzyme essential for the replication of the human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS. RT catalyzes the conversion of single-stranded viral RNA into double-stranded DNA. This newly synthesized DNA is then integrated into the host genome, enabling viral replication and persistence. HIV-1 RT is an asymmetric heterodimer composed of two subunits: p66 and p51. The p66 subunit contains both polymerase and RNase H domains; p51 primarily provides structural support. RT’s activities are crucial for converting HIV’s single-stranded RNA genome into double-stranded linear DNA within infected cells’ cytoplasm.
NRTIs mimic natural nucleotides, causing chain termination. NNRTIs bind to an allosteric pocket, inhibiting polymerization noncompetitively.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Immunodeficiency Virus Type 1 Reverse Transcriptase (None).